276 related articles for article (PubMed ID: 14578761)
21. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients.
Mathias HC; Ozalp F; Will MB; Borland W; Payne C; Kerr M; Lockhart J; Murday AJ
J Heart Lung Transplant; 2005 Dec; 24(12):2137-43. PubMed ID: 16364862
[TBL] [Abstract][Full Text] [Related]
22. [C0 vs C2 levels and their implications in kidney transplantation].
Cuero C; Delgado E; de González M; Medina C; Vernaza A; Moscoso J
Rev Med Panama; 2002; 27():30-3. PubMed ID: 16737196
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
Zhang Y; Zhang XD; Wang Y
Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829
[TBL] [Abstract][Full Text] [Related]
24. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
Hangler HB; Ruttmann E; Geltner C; Bucher B; Nagiller J; Laufer G; Mueller LC
Clin Transplant; 2008; 22(1):35-40. PubMed ID: 18217903
[TBL] [Abstract][Full Text] [Related]
25. Can cyclosporine blood level be reduced to half after heart transplantation?
Wang SS; Chou NK; Chi NH; Huang SC; Wu IH; Wang CH; Yu HY; Chen YS; Tsao CI; Ko WJ; Shun CT
Transplant Proc; 2010 Apr; 42(3):930-3. PubMed ID: 20430207
[TBL] [Abstract][Full Text] [Related]
26. Utility of c2 monitoring in prediction of diastolic dysfunction in renal transplant recipients.
Kirkpantur A; Yilmaz R; Abali G; Arici M; Altun B; Aki T; Erkan I; Bakkaloglu M; Yasavul U; Turgan C
Transplant Proc; 2008; 40(1):171-3. PubMed ID: 18261577
[TBL] [Abstract][Full Text] [Related]
27. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
Cantarovich M; Besner JG; Barkun JS; Elstein E; Loertscher R
Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517
[TBL] [Abstract][Full Text] [Related]
28. Long-term comparative results of C0 and C2 monitoring of CyA in renal transplanted patients.
Paydaş S; Balal M; Sertdemir Y; Seyrek N; Karayaylali I
Ren Fail; 2005; 27(4):409-13. PubMed ID: 16060128
[TBL] [Abstract][Full Text] [Related]
29. Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0.
Loichot C; Bentue-Ferrer D; Bernard N; Bonardet A; Boulieu R; Kergueris MF; Paintaud G; Peytavin G; Simon N; Marquet P;
Fundam Clin Pharmacol; 2006 Feb; 20(1):91-6. PubMed ID: 16448399
[TBL] [Abstract][Full Text] [Related]
30. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study.
Iversen M; Nilsson F; Sipponen J; Eiskjaer H; Mared L; Bergan S; Nyström U; Fagertun HE; Solbu D; Simonsen S
J Heart Lung Transplant; 2009 Sep; 28(9):919-26. PubMed ID: 19716045
[TBL] [Abstract][Full Text] [Related]
31. Optimal blood concentration of cyclosporine among Iranian kidney transplant recipients.
Rostami Z; Einollahi B; Morshedi J; Teimoori M
Iran J Kidney Dis; 2012 Sep; 6(5):373-9. PubMed ID: 22976264
[TBL] [Abstract][Full Text] [Related]
32. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients.
Takatsuki M; Chen CL; Chen YS; Wang CC; Lin CC; Yang CH; Yong CC; Liu YW
Clin Transplant; 2004 Dec; 18(6):694-9. PubMed ID: 15516246
[TBL] [Abstract][Full Text] [Related]
33. Cyclosporine trough (C0) and 2-hour postdose (C2) levels: which one is a predictor of graft loss?
Nemati E; Einollahi B; Taheri S; Moghani-Lankarani M; Kalantar E; Simforoosh N; Nafar M; Saadat AR
Transplant Proc; 2007 May; 39(4):1223-4. PubMed ID: 17524938
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and side-effects of cyclosporine dose monitoring with levels 6 h after the morning dose in heart transplant patients.
Cantarovich M; Besner JG; Fitchett DH; Latter DA
Clin Transplant; 1997 Oct; 11(5 Pt 1):399-405. PubMed ID: 9361930
[TBL] [Abstract][Full Text] [Related]
35. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients.
Cole E; Maham N; Cardella C; Cattran D; Fenton S; Hamel J; O'Grady C; Smith R
Transplantation; 2003 Jun; 75(12):2086-90. PubMed ID: 12829917
[TBL] [Abstract][Full Text] [Related]
36. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation.
Rodrigo E; Ruiz JC; Angeles de Cos M; Ruiz J; Gago M; Piñera C; Sánchez B; González-Cotorruelo J; Gómez-Alamillo C; Arias M
Transplant Proc; 2009; 41(6):2328-31. PubMed ID: 19715910
[TBL] [Abstract][Full Text] [Related]
37. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
John U; Ullrich S; Roskos M; Misselwitz J
Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
[TBL] [Abstract][Full Text] [Related]
38. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation.
Morton JM; Aboyoun CL; Malouf MA; Plit ML; Glanville AR
J Heart Lung Transplant; 2004 Sep; 23(9):1035-9. PubMed ID: 15454168
[TBL] [Abstract][Full Text] [Related]
39. Neoral dose adjustment after conversion from C0 to C2 monitoring in stable renal transplant recipients: a prospective single center study.
Sandrini S; Bossini N; Setti G; Mazzucchelli C; Maiorca P; Cancarini G
J Nephrol; 2004; 17(2):284-90. PubMed ID: 15293530
[TBL] [Abstract][Full Text] [Related]
40. Single daily dose administration of cyclosporine in renal transplant recipients.
Halim MA; Said T; Al-Otaibi T; Eleawa S; Al-Maged H; Gawish AE; Nair P; Al-Muzairai I; Nampoory MR; Al-Mousawi M
Transplant Proc; 2007 May; 39(4):1225-7. PubMed ID: 17524939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
